Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00347
|
|||||
Drug Name |
Olmesartan medoxomil
|
|||||
Synonyms |
Benevas; Benicar; Benicar (TN); Benicar, Olmetec,Olmesartan; Berlin-Chemie Brand of Olmesartan Medoxomil; Forest Brand of Olmesartan Medoxomil; Olmesartan medoximil; Olmesartan medoxomil (JAN/USAN); Olmetec; Olmetec (TN); Olvance; Sankyo Brand of Olmesartan Medoxomil
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | High blood pressure [ICD11: BA00] | Approved | [1] | |||
Therapeutic Class |
Antihypertensive Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C29H30N6O6
|
|||||
Canonical SMILES |
CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O
|
|||||
InChI |
InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
|
|||||
InChIKey |
UQGKUQLKSCSZGY-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 144689-63-4
|
|||||
Pharmaceutical Properties | Molecular Weight | 558.6 | Topological Polar Surface Area | 154 | ||
Heavy Atom Count | 41 | Rotatable Bond Count | 11 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 10 | |||
XLogP |
3.8
|
|||||
PubChem CID | ||||||
PubChem SID |
10242742
, 103770675
, 104253234
, 104373834
, 11364900
, 11367462
, 11370024
, 11372810
, 11374179
, 11378194
, 11484167
, 11488322
, 11491491
, 11492555
, 11495758
, 11528908
, 12014934
, 124637431
, 124757358
, 124891848
, 125164162
, 125311925
, 125341111
, 126624592
, 126655597
, 126655871
, 126669975
, 14935211
, 26612826
, 26681017
, 26748978
, 26748979
, 29309387
, 48185250
, 48334789
, 53789233
, 57343590
, 7300489
, 7848267
, 78528258
, 81040868
, 81092830
, 85209756
, 85787984
, 92124799
, 92308046
, 92308894
, 92713789
, 93302267
, 93815139
|
|||||
ChEBI ID |
CHEBI:31932
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [3] | ||
MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [3] | ||
OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [3] | ||
OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [3] | ||
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [4] | ||
OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [3] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [5] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | MRP2 | Transporter Info | Km = 14.9 microM | LLC-PK1 cells-MRP2 | [3] | |
MRP4 | Transporter Info | Km = 26.2 microM | LLC-PK1 cells-MRP4 | [3] | ||
OAT1 | Transporter Info | Km = 0.0683 microM | Human embryonic kidney cells (HEK293)-OAT1 | [3] | ||
OAT3 | Transporter Info | Km = 0.12 microM | Human embryonic kidney cells (HEK293)-OAT3 | [3] | ||
OATP1B1 | Transporter Info | Km = 12.8 microM | Human embryonic kidney cells (HEK293)-OATP1B1 | [3] | ||
OATP1B1 | Transporter Info | Km = 42.6 microM | Oocytes-OATP1B1 | [4] | ||
OATP1B3 | Transporter Info | Km = 44.2 microM | Human embryonic kidney cells (HEK293)-OATP1B3 | [3] | ||
OATP1B3 | Transporter Info | Km = 71.8 microM | Oocytes-OATP1B3 | [4] | ||
References | ||||||
1 | Olmesartan medoxomil was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913) | |||||
3 | Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76. | |||||
4 | OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9. | |||||
5 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665) |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.